Comparative Pharmacology
Head-to-head clinical analysis: BETAPACE versus LABETALOL HYDROCHLORIDE IN DEXTROSE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BETAPACE versus LABETALOL HYDROCHLORIDE IN DEXTROSE.
BETAPACE vs LABETALOL HYDROCHLORIDE IN DEXTROSE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Class III antiarrhythmic agent; prolongs cardiac action potential duration and refractory period by blocking potassium channels, primarily IKr.
Competitive antagonist at beta-1 adrenergic receptors (cardiac) and selective alpha-1 adrenergic receptors (vascular smooth muscle). Reduces heart rate, myocardial contractility, and peripheral vascular resistance.
Oral: 80 mg twice daily; may increase up to 160 mg twice daily as needed.
Adult: Initial 0.5-2 mg/min IV infusion, titrate to response; typical maintenance 2-8 mg/min. Max cumulative dose 300 mg.
None Documented
None Documented
12 hours (10-20 hours) in patients with normal renal function; prolonged in renal impairment, requiring dose adjustment
Terminal elimination half-life: 5-8 hours (adults); 8-12 hours (elderly); 2-4 hours (children). Clinical context: half-life may be prolonged in hepatic or renal impairment.
Renal: >90% unchanged drug (sotalol) in urine; biliary/fecal: <10%
Renal: 40-60% as unchanged drug and metabolites; biliary/fecal: ~50% as metabolites; <5% unchanged in feces.
Category C
Category A/B
Beta-Blocker
Alpha/Beta-Blocker